K
Kardigan
Biotech & Life Sciences · South San Francisco, United States · Founded 2023
Heart health company aiming to make cardiovascular disease preventable and curable with innovative drug development MoreLess
Kardigan is a heart health company dedicated to transforming the landscape of cardiovascular medicine. With a leadership team of seasoned biopharma veterans, the company focuses on making cardiovascular disease preventable and curable. Kardigan operates in the biotechnology sector, targeting patients with cardiovascular conditions. The business model revolves around the discovery and development of multiple important medicines at an unprecedented pace, leveraging their deep expertise in cardiovascular drug development. Kardigan's revenue is generated through the commercialization of these medicines, aiming to address the global challenge of cardiovascular disease, which remains a leading cause of death worldwide. The company is driven by a commitment to modernize the discovery and development process, bringing a high level of focus and passion to their mission. Keywords: cardiovascular, heart health, drug development, biotechnology, biopharma, medicine, disease prevention, curable, leadership, expertise
Company overview
Kardigan company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2023
- Headquarters
- South San Francisco, United States
- Employees
- 176
- Open positions
- 7
- Dealroom signal
- 93.8
- Investment activity
- 1 companies · latest Mar 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Kardigan funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Jun 2026 | $400M | $1.5B | Undisclosed | ↗ |
| SERIES BOther financing | Oct 2025 | $254M | $1B | Fidelity Investments · ARCH Venture Partners · T. Rowe Price · Sequoia Heritage | ↗ |
| SERIES AOther financing | Feb 2025 | $300M | $1.2B | ARCH Venture Partners · Sequoia Heritage · Perceptive Advisors | ↗ |
| SPINOUTOther financing | Jan 2023 | $0 | — | Mayo Clinic | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$202M | — |
| 2025 | $0 | — | −$202M | — |
| 2024 | $0 | — | −$103M | — |
Growth signals
Kardigan website traffic
Latest recorded traffic for Kardigan is 12K monthly website visits, up 100% over the last three months. Kardigan's team grew 193.3% over the past year.
Hiring
Open positions at Kardigan
Current openings linked to this company in Dealroom.
Comparisons
Kardigan compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Firefly BioUnlocking new classes of payloads to maximize the potential of ADCs |
South San Francisco, United States | Acquired | 24 | $94M | $1B |
 Orna TherapeuticsOrna Therapeutics - Ahead of the Curve |
Cambridge, United States | Acquired | |||
 Sana BiotechnologyFocused on creating and delivering engineered cells as medicines for patients |
Seattle, United States | Operational | |||
 MeiraGTxClinical-stage genetic medicine using regulatable riboswitch technology |
London, United Kingdom | Operational | |||
 BioNTechDevelops personalized immunotherapies with a focus on cancer medicine |
Mainz, Germany | Operational | |||
 Orchard TherapeuticsHematopoietic stem cell gene therapies for rare diseases |
London, United Kingdom | Acquired | |||
 Cardior PharmaceuticalsNon-coding RNA-based therapeutics in heart failure |
Hanover, Germany | Acquired | |||
 SansanimaHuman cell-based assays replacing animal testing. |
Sheffield, United Kingdom | Operational |
Capital deployed
Kardigan investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Kardigan's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Kardigan has talent and traffic
team presence
In the news
Latest news about Kardigan
Recent press, funding announcements, and product moves mentioning Kardigan — open to read from the original sources.
Market sentiment
What the market is saying about Kardigan
An AI-synthesized read of the highest-engagement posts about Kardigan on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kardigan’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.